title: Hypoxia: The Force that Drives Chronic Kidney Disease.
abstract: In the United States the prevalence of end-stage renal disease (ESRD) reached epidemic proportions in 2012 with over 600,000 patients being treated. The rates of ESRD among the elderly are disproportionally high. Consequently, as life expectancy increases and the baby-boom generation reaches retirement age, the already heavy burden imposed by ESRD on the US health care system is set to increase dramatically. ESRD represents the terminal stage of chronic kidney disease (CKD). A large body of evidence indicating that CKD is driven by renal tissue hypoxia has led to the development of therapeutic strategies that increase kidney oxygenation and the contention that chronic hypoxia is the final common pathway to end-stage renal failure. Numerous studies have demonstrated that one of the most potent means by which hypoxic conditions within the kidney produce CKD is by inducing a sustained inflammatory attack by infiltrating leukocytes. Indispensable to this attack is the acquisition by leukocytes of an adhesive phenotype. It was thought that this process resulted exclusively from leukocytes responding to cytokines released from ischemic renal endothelium. However, recently it has been demonstrated that leukocytes also become activated independent of the hypoxic response of endothelial cells. It was found that this endothelium-independent mechanism involves leukocytes directly sensing hypoxia and responding by transcriptional induction of the genes that encode the β2-integrin family of adhesion molecules. This induction likely maintains the long-term inflammation by which hypoxia drives the pathogenesis of CKD. Consequently, targeting these transcriptional mechanisms would appear to represent a promising new therapeutic strategy.
authors: Kabara Cancer Research Institute, La Crosse, WI.
authors: Qiangwei
authors: Q
authors: Fu
authors: Mucosal Inflammation Program and University of Colorado School of Medicine, Aurora, CO.
authors: Sean P
authors: SP
authors: Colgan
authors: University of Wisconsin School of Medicine and Public Health, Madison, WI simon.shelley@leukemiatherapeutics.com.
authors: Carl Simon
authors: CS
authors: Shelley
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000150:complications; D000818:Animals; D050197:Atherosclerosis / Q000150:complications; D002448:Cell Adhesion; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006943:Hyperglycemia / Q000150:complications; D006973:Hypertension / Q000150:complications; D000860:Hypoxia; D007249:Inflammation; D039641:Integrin beta Chains / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000175:diagnosis* / Q000473:pathology*; D017493:Leukocyte Common Antigens / Q000378:metabolism; D007962:Leukocytes / Q000166:cytology; D051917:Leukosialin / Q000378:metabolism; D008875:Middle Aged; D010641:Phenotype; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis* / Q000473:pathology*; D012891:Sleep Apnea Syndromes / Q000150:complications; D012907:Smoking; D014158:Transcription, Genetic; D015533:Transcriptional Activation
chemical_list: D039641:Integrin beta Chains; D051917:Leukosialin; C465014:SPN protein, human; D017493:Leukocyte Common Antigens; C516769:PTPRC protein, human
keywords: CD43; CD45; Gene transcription; Hypoxia; Kidney disease; Leukocyte adhesion; β2-integrins